Q1FY24 Results, Press Release and Investor Presentation August 10, 2023

Alkem enters into a co-development and license agreement with Biosergen AB September 25, 2023 Source link

Alkem Laboratories forays into Ophthalmology July 6, 2023 Source link

Alkem Laboratories launches Cetuxa. World’s first biosimilar of Cetuximab for Head and Neck Cancer. May 29, 2023 Source link

Q4FY23 Results, Press Release and Investor Presentation May 19, 2023 Source link

Closure of US FDA Inspection at Ankleshwar April 7, 2023 Source link

Closure of US FDA Inspection at Indore February 23, 2023 Source link